FDA roundup

Restricted access

Keryx Pharmaceuticals (Boston) announced that the US Food and Drug Administration (FDA) will review its drug Auryxia (ferric citrate) for use in patients who have iron deficiency anemia and non-dialysis–dependent chronic kidney disease (CKD). Ferric citrate is a phosphate binder indicated for controlling serum phosphorus levels, typically in patients with CKD who are on dialysis.

A review for the new use of the drug should be complete by Nov. 6, 2017, according to Drugs.com.

The supplemental New Drug Application (NDA) is based on data from a 2-week controlled, phase 3 trial in 234 adults with non-dialysis–dependent CKD. Patients

Save